Drug intelligence / Profile preview

beta-blocker + ACE inhibitor

Development stage: Unknown
Lead developer: Sun Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

A fixed-dose combination medication that combines a beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor. This combination targets both the sympathetic nervous system and the renin-angiotensin-aldosterone system to provide effective blood pressure control and cardiovascular protection. The complementary mechanisms of action make it particularly useful for treating hypertension, heart failure, and for secondary prevention after myocardial infarction.

Brand names: Prolomet REmbeta-RAce Revelol
Other names: beta-adrenergic receptor antagonists + angiotensin-converting enzyme inhibitorsbeta-blockers and ACE inhibitorsbeta-blockers and ACE inhibitors/ARBs

Targets

ADRB1 (β1)ADRB2 (β2)ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on beta-blocker + ACE inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-blocker + ACE inhibitor.

Explore the full profile